Advertisement Endo appoints new president and CEO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Endo appoints new president and CEO

Endo Pharmaceuticals Holdings has named David Holveck as president, CEO and a director of the company, effective April 1, 2008.

Mr Holveck was most recently president of Johnson & Johnson Development Corporation and vice president, corporate development of Johnson & Johnson. He received a BS in education and science from West Chester University.

Roger Kimmel, chairman of the board of directors of Endo, said: “Dave Holveck is the ideal executive to lead Endo Pharmaceuticals as it pursues growth opportunities and enhanced shareholder value. He has a track record of strong performance, successfully managing product development, building great organizations and creating value.”